This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:starting:physician:reluctant [04.15.2019] – [Ascertain if reluctance is a provider problem or a bureaucracy problem] sallieq | home:starting:physician:reluctant [04.29.2019] – [Read more] sallieq | ||
---|---|---|---|
Line 163: | Line 163: | ||
==== Ascertain if reluctance is a provider problem or a bureaucracy problem ==== | ==== Ascertain if reluctance is a provider problem or a bureaucracy problem ==== | ||
- | In Australia, physicians must now ring Canberra for permission to prescribe off-label. | + | In Australia, physicians must now approach |
- | I expect some other countries also have centralised control, in which case patients may need to research | + | < |
+ | |||
+ | He simply smiled and wrote me 2 prescriptions: | ||
+ | |||
+ | I expect some other countries also have centralised control, in which case patients may need to research | ||
=== Specific research === | === Specific research === | ||
Line 172: | Line 176: | ||
[[home: | [[home: | ||
- | OLM refs to print; | + | OLMesartan references |
- | including | + | include |
- | Dose timing | + | Dose timing |
+ | {{ : | ||
+ | {{ : | ||
+ | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
short extract for each research study follows: | short extract for each research study follows: | ||
- | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
- | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed> | ||
- | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | + | Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. (({{pubmed> |
- | 10) Alzheimer' | + | |
- | prevent migraines (({{pubmed> | + | |
- | inhibit liver fibrosis and aid liver healing (({{pubmed> | + | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (3 mg/kg) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)(({{pubmed> |
- | 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed> | + | |
- | protect the mitochondria from age-associated damage from oxidation (({{pubmed> | + | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> |
- | reduce liver fibrosis (({{pubmed> | + | |
- | treatment of anxiety and stress-related disorders (({{pubmed> | + | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity & apoptosis induction against tumour cells in breast cancer (({{pubmed> |
- | inflammation in myocarditis (({{pubmed> | + | 10) |
- | C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed> | + | |
- | cytokine damage (({{pubmed> | + | Alzheimer' |
+ | |||
+ | |||
+ | prevent migraines (({{pubmed> | ||
+ | |||
+ | |||
+ | inhibit liver fibrosis and aid liver healing (({{pubmed> | ||
+ | |||
+ | |||
+ | 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats (({{pubmed> | ||
+ | |||
+ | |||
+ | protect the mitochondria from age-associated damage from oxidation (({{pubmed> | ||
+ | |||
+ | |||
+ | reduce liver fibrosis (({{pubmed> | ||
+ | |||
+ | |||
+ | treatment of anxiety and stress-related disorders (({{pubmed> | ||
+ | |||
+ | |||
+ | inflammation in myocarditis (({{pubmed> | ||
+ | |||
+ | |||
+ | C-reactive protein, one of the acute phase proteins that increase during systemic inflammation (({{pubmed> | ||
+ | |||
+ | |||
+ | cytokine damage (({{pubmed> | ||
+ | |||
+ | in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | ||
+ | |||
+ | renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | ||
+ | |||
+ | olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed> | ||
+ | |||
+ | |||
+ | * treatment with olmesartan inhibited bone loss (({{pubmed> | ||
+ | |||
+ | |||
+ | * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
+ | |||
+ | |||
+ | * decreases viability of malignant cell lines(({{pubmed> | ||
+ | |||
+ | |||
+ | * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed> | ||
+ | |||
+ | |||
+ | * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | ||
+ | |||
+ | |||
+ | * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | ||
+ | |||
+ | |||
+ | * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | ||
+ | |||
+ | |||
+ | * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed> | ||
+ | |||
+ | |||
+ | Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed> | ||
+ | |||
+ | |||
+ | olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | ||
+ | |||
+ | |||
+ | decreases viability of malignant cell lines (({{pubmed> | ||
+ | |||
+ | |||
+ | carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced | ||
+ | the volume of larger atherosclerotic plaques (({{pubmed> | ||
- | in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | + | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> |
- | renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | ||
- | olmesartan | + | improvement of glycemic control & insulin resistance was only observed in olmesartan |
- | * treatment with olmesartan inhibited bone loss (({{pubmed> | + | OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> |
- | * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | + | |
- | * decreases viability of malignant cell lines(({{pubmed> | + | |
- | * carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed> | + | |
- | * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | + | |
- | * improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | + | |
- | * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | + | |
- | * prevention of microalbuminuria in patients with type 2 diabetes and hypertension (({{pubmed> | + | |
- | Recent studies showed treatment with olmesartan inhibited bone loss (({{pubmed> | + | |
- | olmesartan protects endothelial cells against oxidative stress-mediated cellular injury (({{pubmed> | + | |
- | decreases viability of malignant cell lines (({{pubmed> | + | |
- | carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques (({{pubmed> | + | |
- | improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan (({{pubmed> | + | |
- | improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed> | + | |
- | OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed> | + | |
- | Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/ | + | Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/ |
Line 233: | Line 294: | ||
{{section>: | {{section>: | ||
- | {{tag> | + | {{tag> |
===== Notes and comments ===== | ===== Notes and comments ===== |